Complete financial analysis of Ilyang Pharmaceutical Co.,Ltd (007570.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ilyang Pharmaceutical Co.,Ltd, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- BEENOS Inc. (3328.T) Income Statement Analysis – Financial Results
- Salazar Resources Limited (SRL.V) Income Statement Analysis – Financial Results
- Aldel Financial II Inc. Units (ALDFU) Income Statement Analysis – Financial Results
- F5, Inc. (FFV.DE) Income Statement Analysis – Financial Results
- Ningbo Sunlight Electrical Appliance Co.,Ltd (002473.SZ) Income Statement Analysis – Financial Results
Ilyang Pharmaceutical Co.,Ltd (007570.KS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.ilyang.co.kr
About Ilyang Pharmaceutical Co.,Ltd
Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, antifungal drugs, anti-inflammatory analgesic drugs, insecticides, and vaccines; and health drinks, daily food, supplements, health food, cosmetics, and beverages. In addition, the company offers pharmaceutical raw materials products, such as aluminum hydroxide gel, dried aluminum hydroxide gel, magnesium hydroxide, magnesium hydroxide gel, aluminum hydroxide-magnesium carbonate co-dried gel, magnesium trisilicate, hydrotalcite, almagate, aluminum phosphate, aluminum phosphate gel, aluminum magnesium metasilicate, aluminum magnesium silicate, aluminum magnesium silicopolydrate, magaldrate, magaldrate wet gel, dihydroxy aluminum sodium carbonate, magnesium carbonate, aluminum magnesium hydroxide, synthetic aluminum silicate, and other products. Ilyang Pharmaceutical Co.,Ltd also exports its products to approximately 14 countries. The company was formerly known as Il-Yang Pharm. Ind. Co. and changed its name to Ilyang Pharmaceutical Co., Ltd. in May 1991. Ilyang Pharmaceutical Co.,Ltd was founded in 1946 and is headquartered in Yongin, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 259.04B | 383.81B | 371.35B | 343.33B | 324.57B | 300.04B | 269.81B | 261.61B | 186.29B | 211.80B | 147.73B | 146.46B | 141.16B | 138.49B | 147.69B | 114.61B | 120.29B | 129.86B |
| Cost of Revenue | 149.37B | 167.78B | 166.94B | 161.62B | 145.80B | 145.74B | 133.63B | 138.18B | 102.47B | 118.54B | 87.07B | 89.63B | 84.29B | 79.99B | 88.79B | 77.28B | 73.62B | 76.81B |
| Gross Profit | 109.67B | 216.03B | 204.40B | 181.71B | 178.77B | 154.29B | 136.18B | 123.44B | 83.82B | 93.25B | 60.66B | 56.83B | 56.87B | 58.50B | 58.90B | 37.33B | 46.67B | 53.06B |
| Gross Profit Ratio | 42.34% | 56.29% | 55.04% | 52.93% | 55.08% | 51.43% | 50.47% | 47.18% | 44.99% | 44.03% | 41.06% | 38.80% | 40.29% | 42.24% | 39.88% | 32.57% | 38.80% | 40.85% |
| Research & Development | 23.75B | 25.96B | 20.20B | 19.72B | 15.85B | 12.84B | 12.39B | 10.11B | 7.16B | 8.36B | 7.42B | 1.98B | 2.15B | 2.20B | 827.61M | 1.01B | 632.43M | 484.13M |
| General & Administrative | 5.61B | 7.56B | 6.40B | 6.96B | 18.42B | 18.43B | 14.80B | 12.11B | 7.09B | 10.17B | 5.98B | 7.04B | 6.52B | 5.94B | 5.94B | 4.70B | 5.33B | 5.18B |
| Selling & Marketing | 17.91B | 89.00B | 83.40B | 75.50B | 70.95B | 63.69B | 48.77B | 45.43B | 29.55B | 37.27B | 17.13B | 17.93B | 16.90B | 16.94B | 17.50B | 19.21B | 14.76B | 17.30B |
| SG&A | 23.52B | 96.56B | 89.80B | 82.46B | 89.37B | 82.12B | 63.57B | 57.54B | 36.64B | 47.44B | 23.11B | 24.96B | 23.42B | 22.88B | 23.45B | 23.91B | 20.09B | 22.47B |
| Other Expenses | 48.05B | 53.10B | 53.38B | 45.42B | 41.04B | -4.64B | -1.03B | -738.44M | 888.48M | 371.00M | 593.81M | 397.22M | 959.57M | 1.49B | 2.00B | -1.27B | 3.86B | 1.11B |
| Operating Expenses | 95.32B | 175.62B | 163.38B | 147.61B | 146.26B | 137.57B | 111.75B | 100.25B | 68.30B | 87.01B | 55.93B | 53.60B | 54.05B | 52.57B | 52.32B | 49.32B | 46.51B | 47.08B |
| Cost & Expenses | 244.69B | 343.40B | 330.32B | 309.23B | 292.06B | 283.31B | 245.38B | 238.43B | 170.77B | 205.55B | 143.00B | 143.23B | 138.33B | 132.56B | 141.11B | 126.61B | 120.13B | 123.89B |
| Interest Income | 184.54M | 1.01B | 938.83M | 516.99M | 340.71M | 197.17M | 39.99M | 92.15M | 85.25M | 444.92M | 673.88M | 640.50M | 870.45M | 834.91M | 762.29M | 1.18B | 378.73M | 307.43M |
| Interest Expense | 3.22B | 2.46B | 2.06B | 3.02B | 4.23B | 4.55B | 4.95B | 5.42B | 4.54B | 9.40B | 5.48B | 6.01B | 5.69B | 6.74B | 6.02B | 6.12B | 3.34B | 2.84B |
| Depreciation & Amortization | 8.38B | 8.04B | 7.46B | 7.06B | 7.19B | 7.70B | 81.18B | 11.39B | 9.34B | 10.67B | 5.16B | 3.67B | 3.73B | 3.49B | 3.96B | 3.17B | 3.08B | 3.03B |
| EBITDA | 15.12B | 51.83B | 48.44B | 38.47B | 39.09B | 20.33B | 97.71B | 33.05B | 25.33B | 17.40B | 16.27B | 11.16B | 10.78B | 13.34B | 13.76B | -10.57B | 8.02B | 10.73B |
| EBITDA Ratio | 5.84% | 14.83% | 14.39% | 13.46% | 13.10% | 8.27% | 12.92% | 12.88% | 13.74% | 8.55% | 11.01% | 7.62% | 7.63% | 9.62% | 9.03% | -9.23% | 6.54% | 8.29% |
| Operating Income | 14.35B | 40.41B | 41.03B | 34.10B | 32.51B | 16.72B | 24.43B | 23.18B | 15.52B | 6.25B | 4.73B | 3.23B | 3.79B | 5.92B | 6.58B | -11.99B | 160.82M | 5.97B |
| Operating Income Ratio | 5.54% | 10.53% | 11.05% | 9.93% | 10.02% | 5.57% | 9.06% | 8.86% | 8.33% | 2.95% | 3.20% | 2.20% | 2.68% | 4.28% | 4.45% | -10.46% | 0.13% | 4.60% |
| Total Other Income/Expenses | -1.40B | 923.87M | -2.10B | -5.71B | -4.85B | -8.65B | -6.23B | -6.31B | -4.06B | -8.91B | 897.45M | -1.75B | -4.01B | -2.81B | -4.90B | -7.86B | 1.43B | -1.11B |
| Income Before Tax | 12.95B | 41.33B | 38.93B | 28.39B | 27.66B | 8.07B | 18.21B | 16.24B | 11.45B | -2.66B | 5.63B | 1.48B | 1.37B | 3.11B | 3.77B | -19.85B | 1.59B | 4.86B |
| Income Before Tax Ratio | 5.00% | 10.77% | 10.48% | 8.27% | 8.52% | 2.69% | 6.75% | 6.21% | 6.15% | -1.26% | 3.81% | 1.01% | 0.97% | 2.25% | 2.55% | -17.32% | 1.33% | 3.74% |
| Income Tax Expense | 1.43B | 9.59B | 12.97B | 6.85B | 8.07B | 4.82B | 5.27B | 4.28B | 3.15B | 3.00B | 1.67B | -593.57M | -19.02M | 1.14B | 1.67B | -3.77B | 591.29M | 1.75B |
| Net Income | 11.52B | 31.74B | 25.96B | 21.55B | 19.59B | -4.89B | 6.26B | 5.91B | 3.62B | -10.96B | 3.96B | 2.07B | 1.39B | 1.98B | 1.07B | -16.08B | 1.00B | 3.11B |
| Net Income Ratio | 4.45% | 8.27% | 6.99% | 6.28% | 6.04% | -1.63% | 2.32% | 2.26% | 1.94% | -5.18% | 2.68% | 1.42% | 0.98% | 1.43% | 0.72% | -14.03% | 0.83% | 2.40% |
| EPS | -139.10 | 1.75K | 1.43K | 1.18K | 1.08K | -269.00 | 344.00 | 321.00 | 203.00 | -644.00 | 233.00 | 122.00 | 83.00 | 149.00 | 77.28 | -1.16K | 68.69 | 227.07 |
| EPS Diluted | -139.10 | 1.75K | 1.43K | 1.18K | 1.08K | -268.00 | 344.00 | 321.00 | 203.00 | -612.00 | 233.00 | 122.00 | 83.00 | 149.00 | 77.28 | -1.16K | 68.69 | 227.07 |
| Weighted Avg Shares Out | 18.02M | 18.13M | 18.21M | 18.21M | 18.21M | 18.19M | 18.16M | 18.22M | 17.82M | 17.02M | 17.01M | 16.99M | 16.52M | 13.26M | 13.79M | 13.86M | 14.60M | 13.70M |
| Weighted Avg Shares Out (Dil) | 18.02M | 18.13M | 18.21M | 18.21M | 18.21M | 18.26M | 18.21M | 18.22M | 17.82M | 17.91M | 17.01M | 16.99M | 16.52M | 13.26M | 13.79M | 13.86M | 14.60M | 13.70M |
Source: https://incomestatements.info
Category: Stock Reports